{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:05:23Z","timestamp":1792789523422,"version":"4.5.0"},"reference-count":354,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T00:00:00Z","timestamp":1621468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Marie Sk\u0142odowska-Curie Grant Agreement","award":["722619"],"award-info":[{"award-number":["722619"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease and represents the hepatic expression of several metabolic abnormalities of high epidemiologic relevance. Fat accumulation in the hepatocytes results in cellular fragility and risk of progression toward necroinflammation, i.e., nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and eventually hepatocellular carcinoma. Several pathways contribute to fat accumulation and damage in the liver and can also involve the mitochondria, whose functional integrity is essential to maintain liver bioenergetics. In NAFLD\/NASH, both structural and functional mitochondrial abnormalities occur and can involve mitochondrial electron transport chain, decreased mitochondrial \u03b2-oxidation of free fatty acids, excessive generation of reactive oxygen species, and lipid peroxidation. NASH is a major target of therapy, but there is no established single or combined treatment so far. Notably, translational and clinical studies point to mitochondria as future therapeutic targets in NAFLD since the prevention of mitochondrial damage could improve liver bioenergetics.<\/jats:p>","DOI":"10.3390\/ijms22105375","type":"journal-article","created":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T11:45:57Z","timestamp":1621511157000},"page":"5375","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":127,"title":["Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?"],"prefix":"10.3390","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5476-7376","authenticated-orcid":false,"given":"Agostino","family":"Di Ciaula","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences &amp; Human Oncology, Clinica Medica \u201cA. Murri\u201d, University of Bari Medical School, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Passarella","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Bari Medical School, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harshitha","family":"Shanmugam","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences &amp; Human Oncology, Clinica Medica \u201cA. Murri\u201d, University of Bari Medical School, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marica","family":"Noviello","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences &amp; Human Oncology, Clinica Medica \u201cA. Murri\u201d, University of Bari Medical School, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonilde","family":"Bonfrate","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences &amp; Human Oncology, Clinica Medica \u201cA. Murri\u201d, University of Bari Medical School, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5439-7651","authenticated-orcid":false,"given":"David Q.-H.","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medicine and Genetics, Division of Gastroenterology and Liver Diseases, Marion Bessin Liver Research Center, Einstein-Mount Sinai Diabetes Research Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5359-1471","authenticated-orcid":false,"given":"Piero","family":"Portincasa","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences &amp; Human Oncology, Clinica Medica \u201cA. Murri\u201d, University of Bari Medical School, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Di Ciaula, A., Baj, J., Garruti, G., Celano, G., De Angelis, M., Wang, H.H., Di Palo, D.M., Bonfrate, L., Wang, D.Q.-H., and Portincasa, P. (2020). Liver Steatosis, Gut-Liver Axis, Microbiome and Environmental Factors. A Never-Ending Bidirectional Cross-Talk. J. Clin. Med., 9.","DOI":"10.3390\/jcm9082648"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Di Palo, D.M., Garruti, G., Di Ciaula, A., Molina-Molina, E., Shanmugam, H., De Angelis, M., and Portincasa, P. (2020). Increased Colonic Permeability and Lifestyles as Contributing Factors to Obesity and Liver Steatosis. Nutrients, 12.","DOI":"10.3390\/nu12020564"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Di Ciaula, A., Carbone, F., Shanmugham, H., Molina-Molina, E., Bonfrate, L., Ministrini, S., Montecucco, F., and Portincasa, P. (2021). Adiponectin involved in portal flow hepatic extraction of 13C-metacethin in obesity and non-alcoholic fatty liver. Eur. J. Intern. Med.","DOI":"10.1016\/j.ejim.2021.03.036"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1172\/JCI93465","article-title":"Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis","volume":"127","author":"Caussy","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1053\/j.gastro.2020.01.053","article-title":"Toward Genetic Prediction of Nonalcoholic Fatty Liver Disease Trajectories: PNPLA3 and Beyond","volume":"158","author":"Krawczyk","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Dai, G., Liu, P., Li, X., Zhou, X., and He, S. (2019). Association between PNPLA3 rs738409 polymorphism and nonalcoholic fatty liver disease (NAFLD) susceptibility and severity: A meta-analysis. Medicine, 98.","DOI":"10.1097\/MD.0000000000014324"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/eurheartj\/ehx662","article-title":"Liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease: Mendelian randomization and meta-analysis of 279 013 individuals","volume":"39","author":"Lauridsen","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/1724600818812471","article-title":"Correlation between PNPLA3 rs738409 polymorphism and hepatocellular carcinoma: A meta-analysis of 10,330 subjects","volume":"34","author":"Huang","year":"2019","journal-title":"Int. J. Biol. Markers"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.bpg.2010.08.005","article-title":"Nonalcoholic fatty liver disease","volume":"24","author":"Krawczyk","year":"2010","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1055\/s-0033-1358525","article-title":"PNPLA3-associated steatohepatitis: Toward a gene-based classification of fatty liver disease","volume":"33","author":"Krawczyk","year":"2013","journal-title":"Semin. Liver Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1053\/j.gastro.2016.01.032","article-title":"The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent","volume":"150","author":"Mancina","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1053\/j.gastro.2015.01.038","article-title":"TM6SF2: Catch-22 in the fight against nonalcoholic fatty liver disease and cardiovascular disease?","volume":"148","author":"Kahali","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1111\/apt.15738","article-title":"Review article: The emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis","volume":"51","author":"Carlsson","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Emdin, C.A., Haas, M.E., Khera, A.V., Aragam, K., Chaffin, M., Klarin, D., Hindy, G., Jiang, L., Wei, W.Q., and Feng, Q. (2020). A missense variant in Mitochondrial Amidoxime Reducing Component 1 gene and protection against liver disease. PLoS Genet., 16.","DOI":"10.1371\/journal.pgen.1009503"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa1712191","article-title":"A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease","volume":"378","author":"Cheng","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease","volume":"115","author":"Donnelly","year":"2005","journal-title":"J. Clin. Investig."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12328-010-0182-9","article-title":"The latest idea in NAFLD\/NASH pathogenesis","volume":"3","author":"Ono","year":"2010","journal-title":"Clin. J. Gastroenterol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00109-019-01765-1","article-title":"Innate immune regulatory networks in hepatic lipid metabolism","volume":"97","author":"Bai","year":"2019","journal-title":"J. Mol. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.plipres.2009.05.001","article-title":"Lipolysis and lipid mobilization in human adipose tissue","volume":"48","author":"Lafontan","year":"2009","journal-title":"Prog. Lipid Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"8713","DOI":"10.3390\/ijms15058713","article-title":"Role of mitochondria in nonalcoholic fatty liver disease","volume":"15","author":"Nassir","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.bbalip.2011.09.010","article-title":"Fatty acid transport proteins, implications in physiology and disease","volume":"1821","author":"Kazantzis","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1101\/sqb.2002.67.491","article-title":"SREBPs: Transcriptional mediators of lipid homeostasis","volume":"67","author":"Horton","year":"2002","journal-title":"Cold Spring Harb. Symp. Quant. Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1146\/annurev-pathol-020117-043617","article-title":"Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease","volume":"13","author":"Arab","year":"2018","journal-title":"Annu. Rev. Pathol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/hep.28709","article-title":"Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives","volume":"65","author":"Arab","year":"2017","journal-title":"Hepatology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"s4","DOI":"10.5604\/01.3001.0010.5493","article-title":"Bile Acid Physiology","volume":"16","author":"Garruti","year":"2017","journal-title":"Ann. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial","volume":"385","author":"Loomba","year":"2015","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Portincasa, P., Di Ciaula, A., Garruti, G., Vacca, M., De Angelis, M., and Wang, D.Q. (2020). Bile Acids and GPBAR-1: Dynamic Interaction Involving Genes, Environment and Gut Microbiome. Nutrients, 12.","DOI":"10.3390\/nu12123709"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/nrm3699","article-title":"The biophysics and cell biology of lipid droplets","volume":"14","author":"Thiam","year":"2013","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.tem.2011.04.002","article-title":"Expanding roles for lipid droplets","volume":"22","author":"Greenberg","year":"2011","journal-title":"Trends Endocrinol. Metab. TEM"},{"key":"ref_31","first-page":"387626","article-title":"Mitochondrial roles and cytoprotection in chronic liver injury","volume":"2012","author":"Hamelin","year":"2012","journal-title":"Biochem. Res. Int."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3748\/wjg.14.193","article-title":"Nonalcoholic fatty liver disease and mitochondrial dysfunction","volume":"14","author":"Wei","year":"2008","journal-title":"World J. Gastroenterol. WJG"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1023\/A:1005564031119","article-title":"Correlation between decreased expression of mitochondrial F0F1-ATP synthase and low regenerating capability of the liver after partial hepatectomy in hypothyroid rats","volume":"32","author":"Guerrieri","year":"2000","journal-title":"J. Bioenerg. Biomembr."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.abb.2009.12.016","article-title":"Pyruvate kinase in pig liver mitochondria","volume":"495","author":"Pizzuto","year":"2010","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.bbrc.2017.05.154","article-title":"The occurrence of l-lactate dehydrogenase in the inner mitochondrial compartment of pig liver","volume":"489","author":"Paventi","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1016\/j.febslet.2008.09.042","article-title":"Mitochondria and L-lactate metabolism","volume":"582","author":"Passarella","year":"2008","journal-title":"FEBS Lett."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.freeradbiomed.2020.02.025","article-title":"Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease","volume":"152","author":"Chen","year":"2020","journal-title":"Free Radic. Biol. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cmet.2017.08.002","article-title":"Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases","volume":"27","author":"Samuel","year":"2018","journal-title":"Cell Metab."},{"key":"ref_39","unstructured":"Passarella, S. (2019). Phosphoenolpyruvate (PEP) and Mitochondria in Perspectives on Mitochondrial Transport and Energy Metabolism, Aracne Editrice. [1st ed.]."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.tem.2019.08.006","article-title":"Emerging Molecular Targets for Treatment of Nonalcoholic Fatty Liver Disease","volume":"30","author":"Chen","year":"2019","journal-title":"Trends Endocrinol. Metab. TEM"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bcp.2018.11.020","article-title":"Targeting mitochondria to oppose the progression of nonalcoholic fatty liver disease","volume":"160","author":"Grattagliano","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1053\/j.gastro.2010.09.038","article-title":"Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: A prospective study","volume":"140","author":"Williams","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2036.2011.04724.x","article-title":"Systematic review: The epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults","volume":"34","author":"Vernon","year":"2011","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/aje\/kws448","article-title":"Prevalence of nonalcoholic fatty liver disease in the United States: The Third National Health and Nutrition Examination Survey, 1988\u20131994","volume":"178","author":"Lazo","year":"2013","journal-title":"Am. J. Epidemiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.cgh.2011.03.020","article-title":"Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008","volume":"9","author":"Younossi","year":"2011","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e12958","DOI":"10.1111\/eci.12958","article-title":"Exercising the hepatobiliary-gut axis. The impact of physical activity performance","volume":"48","author":"Wang","year":"2018","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.clinre.2019.04.005","article-title":"Non-Alcoholic Fatty Liver Disease in Non-Obese Individuals: Prevalence, Pathogenesis and Treatment","volume":"43","author":"Krawczyk","year":"2019","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1002\/hep.31150","article-title":"Epidemiological Features of NAFLD From 1999 to 2018 in China","volume":"71","author":"Zhou","year":"2020","journal-title":"Hepatology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s11695-017-2980-3","article-title":"Non-alcoholic fatty liver disease in morbidly obese individuals undergoing bariatric surgery: Prevalence and effect of the pre-bariatric very low calorie diet","volume":"28","author":"Schwenger","year":"2018","journal-title":"Obes. Surg."},{"key":"ref_50","first-page":"1349","article-title":"Liver pathology in morbidly obese patients with and without diabetes","volume":"85","author":"Silverman","year":"1990","journal-title":"Am. J. Gastroenterol. Springer Nat."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e1900942","DOI":"10.1002\/mnfr.201900942","article-title":"Mitochondrial Dysfunction is a Key Pathway that Links Saturated Fat Intake to the Development and Progression of NAFLD","volume":"65","author":"Meex","year":"2021","journal-title":"Mol. Nutr. Food Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/nrgastro.2013.171","article-title":"The global NAFLD epidemic","volume":"10","author":"Loomba","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4093\/dmj.2015.39.1.10","article-title":"Hepatokines as a link between obesity and cardiovascular diseases","volume":"39","author":"Yoo","year":"2015","journal-title":"Diabetes Metab. J."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.ecl.2016.06.005","article-title":"Nonalcoholic Fatty Liver Disease: The New Complication of Type 2 Diabetes Mellitus","volume":"45","author":"Bril","year":"2016","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.cmet.2015.09.023","article-title":"Fetuin B is a secreted hepatocyte factor linking steatosis to impaired glucose metabolism","volume":"22","author":"Meex","year":"2015","journal-title":"Cell Metab."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), and European Association for the Study of Obesity (EASO) (2016). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol., 64, 1388\u20131402.","DOI":"10.1016\/j.jhep.2015.11.004"},{"key":"ref_57","first-page":"434","article-title":"Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnaMed. disease","volume":"55","author":"Ludwig","year":"1980","journal-title":"Mayo Clin. Proc. Mayo Clin."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/hep.510290347","article-title":"Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease","volume":"29","author":"Caldwell","year":"1999","journal-title":"Hepatology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1572-0241.2004.04059.x","article-title":"Ethnic differences in the prevalence of cryptogenic cirrhosis","volume":"99","author":"Browning","year":"2004","journal-title":"Am. J. Gastroenterol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/hep4.1134","article-title":"Natural history of nonalcoholic fatty liver disease: A prospective follow-up study with serial biopsies","volume":"2","author":"Nasr","year":"2018","journal-title":"Hepatol. Commun."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.cgh.2015.07.019","article-title":"Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans is Associated With Nonalcoholic Fatty Liver Disease","volume":"14","author":"Mittal","year":"2016","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_63","unstructured":"(2021, March 16). National Institute of Alcohol Abuse and Alcoholism (NIH), Available online: https:\/\/pubs.niaaa.nih.gov\/publications\/practitioner\/pocketguide\/pocket_guide2.htm."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cld.2017.08.003","article-title":"The Natural History of Nonalcoholic Fatty Liver Disease\u2014An Evolving View","volume":"22","author":"Lindenmeyer","year":"2018","journal-title":"Clin. Liver Dis."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/nrgastro.2016.3","article-title":"Management of NAFLD: A stage-based approach","volume":"13","author":"Rinella","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ejim.2017.10.020","article-title":"Obesity phenotypes and their paradoxical association with cardiovascular diseases","volume":"48","author":"Vecchie","year":"2018","journal-title":"Eur. J. Intern. Med."},{"key":"ref_68","unstructured":"Wang, D.Q.H., and Portincasa, P. (2017). Nonalcoholic fatty liver and gallstone disease. Gallstones. Recent Advances in Epidemiology, Pathogenesis, Diagnosis and Management, Nova Science Publisher Inc."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Oliveira, P. (2018). Mitochondria in liver diseases. Mitochondrial Biology and Experimental Therapeutics, Springer Nature.","DOI":"10.1007\/978-3-319-73344-9"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1210\/en.2015-1866","article-title":"Hepatocyte-Specific Disruption of CD36 Attenuates Fatty Liver and Improves Insulin Sensitivity in HFD-Fed Mice","volume":"157","author":"Wilson","year":"2016","journal-title":"Endocrinology"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1053\/j.gastro.2013.11.049","article-title":"Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease","volume":"146","author":"Lambert","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.cmet.2011.11.004","article-title":"Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease","volume":"14","author":"Sunny","year":"2011","journal-title":"Cell Metab."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jhep.2017.11.014","article-title":"Lipotoxicity and the gut-liver axis in NASH pathogenesis","volume":"68","author":"Marra","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrendo.2017.56","article-title":"Hepatokines: Linking nonalcoholic fatty liver disease and insulin resistance","volume":"13","author":"Meex","year":"2017","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"5637","DOI":"10.1074\/jbc.M807616200","article-title":"Hepatic Lipid Partitioning and Liver Damage in Nonalcoholic Fatty Liver Disease: Role of stearoyl-CoA desaturase","volume":"284","author":"Li","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.jhep.2010.01.003","article-title":"Palmitoleate attenuates palmitate-induced Bim and PUMA up-regulation and hepatocyte lipoapoptosis","volume":"52","author":"Akazawa","year":"2010","journal-title":"J. Hepatol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1194\/jlr.M085613","article-title":"Mitochondrial dysfunction-related lipid changes occur in nonalcoholic fatty liver disease progression","volume":"59","author":"Peng","year":"2018","journal-title":"J. Lipid Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.2337\/dc19-2331","article-title":"Intrahepatic Fat and Postprandial Glycemia Increase After Consumption of a Diet Enriched in Saturated Fat Compared With Free Sugars","volume":"43","author":"Parry","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/hep.21655","article-title":"Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis","volume":"45","author":"Yamaguchi","year":"2007","journal-title":"Hepatology"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.cmet.2016.10.012","article-title":"Physiological Suppression of Lipotoxic Liver Damage by Complementary Actions of HDAC3 and SCAP\/SREBP","volume":"24","author":"Papazyan","year":"2016","journal-title":"Cell Metab."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1194\/jlr.R000034","article-title":"Adoption of PERILIPIN as a unifying nomenclature for the mammalian PAT-family of intracellular lipid storage droplet proteins","volume":"51","author":"Kimmel","year":"2010","journal-title":"J. Lipid Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"38486","DOI":"10.1074\/jbc.M007322200","article-title":"Perilipin A increases triacylglycerol storage by decreasing the rate of triacylglycerol hydrolysis","volume":"275","author":"Brasaemle","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/hep.27409","article-title":"Perilipin 5 improves hepatic lipotoxicity by inhibiting lipolysis","volume":"61","author":"Wang","year":"2015","journal-title":"Hepatology"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1194\/jlr.M700184-JLR200","article-title":"Lysophosphatidylcholine as a death effector in the lipoapoptosis of hepatocytes","volume":"49","author":"Han","year":"2008","journal-title":"J. Lipid Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.metabol.2016.02.014","article-title":"Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease","volume":"65","author":"Mota","year":"2016","journal-title":"Metab. Clin. Exp."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.tem.2012.04.005","article-title":"Role of ceramides in nonalcoholic fatty liver disease","volume":"23","author":"Pagadala","year":"2012","journal-title":"Trends Endocrinol. Metab. TEM"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.cmet.2014.09.015","article-title":"CerS2 haploinsufficiency inhibits beta-oxidation and confers susceptibility to diet-induced steatohepatitis and insulin resistance","volume":"20","author":"Raichur","year":"2014","journal-title":"Cell Metab."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.tem.2015.11.008","article-title":"The Role of Cholesterol in the Pathogenesis of NASH","volume":"27","author":"Ioannou","year":"2016","journal-title":"Trends Endocrinol. Metab. TEM"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.freeradbiomed.2014.10.594","article-title":"Oxysterols induce mitochondrial impairment and hepatocellular toxicity in non-alcoholic fatty liver disease","volume":"75","author":"Bellanti","year":"2014","journal-title":"Free Radic. Biol. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.cotox.2019.03.001","article-title":"Human in vitro models of nonalcoholic fatty liver disease","volume":"16","author":"Sturla","year":"2019","journal-title":"Curr. Opin. Toxicol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.cmet.2012.03.007","article-title":"The role of endoplasmic reticulum in hepatic lipid homeostasis and stress signaling","volume":"15","author":"Fu","year":"2012","journal-title":"Cell Metab."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nature13478","article-title":"The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes","volume":"510","author":"Perry","year":"2014","journal-title":"Nature"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1194\/jlr.R066514","article-title":"Lipid signaling and lipotoxicity in metaflammation: Indications for metabolic disease pathogenesis and treatment","volume":"57","author":"Ertunc","year":"2016","journal-title":"J. Lipid Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1146\/annurev-pathmechdis-012418-013003","article-title":"Innate Immune Signaling in Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases","volume":"14","author":"Cai","year":"2019","journal-title":"Annu. Rev. Pathol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1002\/hep.30506","article-title":"The Role of Innate Immune Cells in Nonalcoholic Steatohepatitis","volume":"70","author":"Cai","year":"2019","journal-title":"Hepatology"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/hep.26751","article-title":"Interferon regulatory factor 3 constrains IKKbeta\/NF-kappaB signaling to alleviate hepatic steatosis and insulin resistance","volume":"59","author":"Wang","year":"2014","journal-title":"Hepatology"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1567-7249(03)00008-4","article-title":"The role of mitochondrial transport in energy metabolism","volume":"2","author":"Passarella","year":"2003","journal-title":"Mitochondrion"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Serviddio, G., Giudetti, A.M., Bellanti, F., Priore, P., Rollo, T., Tamborra, R., Siculella, L., Vendemiale, G., Altomare, E., and Gnoni, G.V. (2011). Oxidation of hepatic carnitine palmitoyl transferase-I (CPT-I) impairs fatty acid beta-oxidation in rats fed a methionine-choline deficient diet. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0024084"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/hep.1840380426","article-title":"Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis","volume":"38","author":"Martin","year":"2003","journal-title":"Hepatology"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mito.2017.08.015","article-title":"Mitochondrial adaptation in steatotic mice","volume":"40","author":"Einer","year":"2018","journal-title":"Mitochondrion"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1053\/gast.2001.23256","article-title":"Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities","volume":"120","author":"Sanyal","year":"2001","journal-title":"Gastroenterology"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1530\/JME-15-0101","article-title":"Glucose fluctuation increased hepatocyte apoptosis under lipotoxicity and the involvement of mitochondrial permeability transition opening","volume":"55","author":"Yin","year":"2015","journal-title":"J. Mol. Endocrinol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.freeradbiomed.2017.09.026","article-title":"Redox imbalance due to the loss of mitochondrial NAD(P)-transhydrogenase markedly aggravates high fat diet-induced fatty liver disease in mice","volume":"113","author":"Navarro","year":"2017","journal-title":"Free Radic. Biol. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"G265","DOI":"10.1152\/ajpgi.00278.2013","article-title":"Involvement of the mitochondrial permeability transition pore in chronic ethanol-mediated liver injury in mice","volume":"306","author":"King","year":"2014","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.jhep.2010.11.006","article-title":"Drug-induced toxicity on mitochondria and lipid metabolism: Mechanistic diversity and deleterious consequences for the liver","volume":"54","author":"Begriche","year":"2011","journal-title":"J. Hepatol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jhep.2004.02.013","article-title":"The spectrum expanded: Cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease","volume":"40","author":"Caldwell","year":"2004","journal-title":"J. Hepatol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/j.bbabio.2007.07.011","article-title":"Mitochondrial dysfunction in rat with nonalcoholic fatty liver Involvement of complex I, reactive oxygen species and cardiolipin","volume":"1767","author":"Petrosillo","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3389\/fnut.2017.00042","article-title":"The Nutraceutic Silybin Counteracts Excess Lipid Accumulation and Ongoing Oxidative Stress in an In Vitro Model of Non-Alcoholic Fatty Liver Disease Progression","volume":"4","author":"Vecchione","year":"2017","journal-title":"Front. Nutr."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.tem.2016.11.006","article-title":"Mitochondrial Adaptation in Nonalcoholic Fatty Liver Disease: Novel Mechanisms and Treatment Strategies","volume":"28","author":"Sunny","year":"2017","journal-title":"Trends Endocrinol. Metab.TEM"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1042\/CS20050346","article-title":"Liver breath tests non-invasively predict higher stages of non-alcoholic steatohepatitis","volume":"111","author":"Portincasa","year":"2006","journal-title":"Clin. Sci."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1111\/j.1572-0241.2003.07725.x","article-title":"Hepatic mitochondrial beta-oxidation in patients with nonalcoholic steatohepatitis assessed by 13 C-octanoate breath test","volume":"98","author":"Miele","year":"2003","journal-title":"Am. J. Gastroenterol."},{"key":"ref_112","first-page":"72","article-title":"Breath tests with novel 13C-substrates for clinical studies of liver mitochondrial function in health and disease","volume":"17","author":"Grattagliano","year":"2013","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/978-1-4939-1875-1_12","article-title":"Exploring liver mitochondrial function by (1)(3)C-stable isotope breath tests: Implications in clinical biochemistry","volume":"1241","author":"Grattagliano","year":"2015","journal-title":"Methods Mol. Biol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/gastro\/gou068","article-title":"Dynamic carbon 13 breath tests for the study of liver function and gastric emptying","volume":"3","author":"Bonfrate","year":"2015","journal-title":"Gastroenterol. Rep."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"448","DOI":"10.2337\/dc10-1076","article-title":"Liver ATP synthesis is lower and relates to insulin sensitivity in patients with type 2 diabetes","volume":"34","author":"Schmid","year":"2011","journal-title":"Diabetes Care"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.cmet.2015.04.004","article-title":"Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis","volume":"21","author":"Koliaki","year":"2015","journal-title":"Cell Metab."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Fletcher, J.A., Deja, S., Satapati, S., Fu, X., Burgess, S.C., and Browning, J.D. (2019). Impaired ketogenesis and increased acetyl-CoA oxidation promote hyperglycemia in human fatty liver. JCI Insight, 5.","DOI":"10.1172\/jci.insight.127737"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1172\/JCI82204","article-title":"Mitochondrial metabolism mediates oxidative stress and inflammation in fatty liver","volume":"125","author":"Satapati","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3748\/wjg.v11.i1.142","article-title":"Measurement of hepatic functional mass by means of 13C-methacetin and 13C-phenylalanine breath tests in chronic liver disease: Comparison with Child-Pugh score and serum bile acid levels","volume":"11","author":"Festi","year":"2005","journal-title":"World J. Gastroenterol. WJG"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/j.1365-2362.2010.02331.x","article-title":"13C-breath tests for clinical investigation of liver mitochondrial function","volume":"40","author":"Grattagliano","year":"2010","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jss.2008.09.029","article-title":"Liver function as assessed by breath tests in patients with hepatocellular carcinoma","volume":"157","author":"Palmieri","year":"2009","journal-title":"J. Surg. Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.dld.2010.01.001","article-title":"(13)C-octanoic acid breath test (OBT) with a new test meal (EXPIROGer): Toward standardization for testing gastric emptying of solids","volume":"42","author":"Perri","year":"2010","journal-title":"Dig. Liver Dis."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.jhep.2015.01.032","article-title":"Sab (Sh3bp5) dependence of JNK mediated inhibition of mitochondrial respiration in palmitic acid induced hepatocyte lipotoxicity","volume":"62","author":"Win","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/hep.28245","article-title":"Eliciting the mitochondrial unfolded protein response by nicotinamide adenine dinucleotide repletion reverses fatty liver disease in mice","volume":"63","author":"Gariani","year":"2016","journal-title":"Hepatology"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"E311","DOI":"10.1152\/ajpendo.00161.2015","article-title":"Cross-talk between branched-chain amino acids and hepatic mitochondria is compromised in nonalcoholic fatty liver disease","volume":"309","author":"Sunny","year":"2015","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Mehta, R., Jeiran, K., Koenig, A.B., Otgonsuren, M., Goodman, Z., Baranova, A., and Younossi, Z. (2016). The role of mitochondrial genomics in patients with non-alcoholic steatohepatitis (NASH). BMC Med. Genet., 17.","DOI":"10.1186\/s12881-016-0324-0"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/ajcn\/86.3.661","article-title":"Nitrosative stress predicts the presence and severity of nonalcoholic fatty liver at different stages of the development of insulin resistance and metabolic syndrome: Possible role of vitamin A intake","volume":"86","author":"Musso","year":"2007","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"4967","DOI":"10.3748\/wjg.v13.i37.4967","article-title":"Novel interactions of mitochondria and reactive oxygen\/nitrogen species in alcohol mediated liver disease","volume":"13","author":"Mantena","year":"2007","journal-title":"World J. Gastroenterol. WJG"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/s-0035-1562944","article-title":"Systemic complications of nonalcoholic fatty liver disease: When the liver is not an innocent bystander","volume":"35","author":"Vanni","year":"2015","journal-title":"Semin. Liver Dis."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/hep.25967","article-title":"GSK3-mediated VDAC phosphorylation controls outer mitochondrial membrane permeability during lipid accumulation","volume":"57","author":"Martel","year":"2013","journal-title":"Hepatology"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.freeradbiomed.2009.03.004","article-title":"Cytochrome c\/cardiolipin relations in mitochondria: A kiss of death","volume":"46","author":"Kagan","year":"2009","journal-title":"Free Radic. Biol. Med."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"e2390","DOI":"10.1038\/cddis.2016.280","article-title":"Activation of necroptosis in human and experimental cholestasis","volume":"7","author":"Afonso","year":"2016","journal-title":"Cell Death Dis."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1053\/jhep.2000.9034","article-title":"Cytochrome P450-generated reactive metabolites cause mitochondrial permeability transition, caspase activation, and apoptosis in rat hepatocytes","volume":"32","author":"Haouzi","year":"2000","journal-title":"Hepatology"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/sj.cdd.4400780","article-title":"VDAC regulation by the Bcl-2 family of proteins","volume":"7","author":"Tsujimoto","year":"2000","journal-title":"Cell Death Differ."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1111\/j.1471-4159.2006.03820.x","article-title":"Caspase-dependent alteration of the ADP\/ATP translocator triggers the mitochondrial permeability transition which is not required for the low-potassium-dependent apoptosis of cerebellar granule cells","volume":"97","author":"Atlante","year":"2006","journal-title":"J. Neurochem."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.15252\/embr.201643602","article-title":"Mitochondrial permeability transition involves dissociation of F1FO ATP synthase dimers and C-ring conformation","volume":"18","author":"Bonora","year":"2017","journal-title":"Embo Rep."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"16070","DOI":"10.1038\/cddiscovery.2016.70","article-title":"Mitochondrial permeability transition pore induction is linked to formation of the complex of ATPase C-subunit, polyhydroxybutyrate and inorganic polyphosphate","volume":"2","author":"Elustondo","year":"2016","journal-title":"Cell Death Discov."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"9086","DOI":"10.1073\/pnas.1711201114","article-title":"Permeability transition in human mitochondria persists in the absence of peripheral stalk subunits of ATP synthase","volume":"114","author":"He","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1073\/pnas.1702357114","article-title":"Persistence of the mitochondrial permeability transition in the absence of subunit c of human ATP synthase","volume":"114","author":"He","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1152\/physrev.00026.2013","article-title":"Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release","volume":"94","author":"Zorov","year":"2014","journal-title":"Physiol. Rev."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00441-004-0872-z","article-title":"Apoptosis shifts to necrosis via intermediate types of cell death by a mechanism depending on c-myc and bcl-2 expression","volume":"316","author":"Papucci","year":"2004","journal-title":"Cell Tissue Res."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1017\/S0007114517003713","article-title":"20-Week follow-up of hepatic steatosis installation and liver mitochondrial structure and activity and their interrelation in rats fed a high-fat\u2013high-fructose diet","volume":"119","author":"Fouret","year":"2018","journal-title":"Br. J. Nutr."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0168-8278(02)00073-9","article-title":"In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases","volume":"37","author":"Seki","year":"2002","journal-title":"J. Hepatol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12944-020-01210-0","article-title":"Mutual interaction between endoplasmic reticulum and mitochondria in nonalcoholic fatty liver disease","volume":"19","author":"Wang","year":"2020","journal-title":"Lipids Health Dis."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jama.2020.2298","article-title":"Nonalcoholic Steatohepatitis: A Review","volume":"323","author":"Sheka","year":"2020","journal-title":"JAMA"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hep.23276","article-title":"Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis","volume":"51","author":"Promrat","year":"2010","journal-title":"Hepatology"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jhep.2012.02.023","article-title":"Exercise and non-alcoholic fatty liver disease: A systematic review and meta-analysis","volume":"57","author":"Keating","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jhep.2015.02.022","article-title":"Effect of aerobic exercise training dose on liver fat and visceral adiposity","volume":"63","author":"Keating","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis","volume":"149","author":"Friedman","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"603","DOI":"10.2337\/diabetes.54.3.603","article-title":"Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes","volume":"54","author":"Petersen","year":"2005","journal-title":"Diabetes"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s00125-011-2446-4","article-title":"Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of randomised trials","volume":"55","author":"Musso","year":"2012","journal-title":"Diabetologia"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"100203","DOI":"10.1016\/j.jhepr.2020.100203","article-title":"((13)C)-Methacetin breath test provides evidence of subclinical liver dysfunction linked to fat storage but not lifestyle","volume":"3","author":"Shanmugam","year":"2021","journal-title":"JHEP Rep."},{"key":"ref_153","unstructured":"Cerqueira, F.M., Cunha, F.M.d., Silva, C.C., Chausse, B., Romano, R.L., Garcia, C., Colepicolo, P., Medeiros, M.H.G.d., and Kowaltowski, A.J. (2011). Redox state, insulin sensitivity and aging. Resumos, Reuni\u00e3o Anual da Federa\u00e7\u00e3o de Sociedades de Biologia Experimental."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1179\/1351000211Y.0000000014","article-title":"Caloric restriction and redox state: Does this diet increase or decrease oxidant production?","volume":"16","author":"Kowaltowski","year":"2011","journal-title":"Redox Rep."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.freeradbiomed.2013.05.037","article-title":"The effects of dietary restriction on oxidative stress in rodents","volume":"66","author":"Walsh","year":"2014","journal-title":"Free Radic. Biol. Med."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"G987","DOI":"10.1152\/ajpgi.90272.2008","article-title":"Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent","volume":"295","author":"Tetri","year":"2008","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jhep.2017.05.016","article-title":"Treatment of NAFLD with diet, physical activity and exercise","volume":"67","author":"Trenell","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1007\/s11695-015-1691-x","article-title":"Bariatric Surgery and Non-Alcoholic Fatty Liver Disease: A Systematic Review of Liver Biochemistry and Histology","volume":"25","author":"Bower","year":"2015","journal-title":"Obes. Surg."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1053\/j.gastro.2009.04.052","article-title":"Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease","volume":"137","author":"Mathurin","year":"2009","journal-title":"Gastroenterology"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1002\/hep.20251","article-title":"Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss","volume":"39","author":"Dixon","year":"2004","journal-title":"Hepatology"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/oby.2005.140","article-title":"Roux-en-Y gastric bypass improves liver histology in patients with non-alcoholic fatty liver disease","volume":"13","author":"Clark","year":"2005","journal-title":"Obes. Res."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1007\/s11695-011-0579-7","article-title":"Improvement of nonalcoholic fatty liver disease after bariatric surgery in morbidly obese Chinese patients","volume":"22","author":"Tai","year":"2012","journal-title":"Obes. Surg."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.cgh.2018.10.017","article-title":"Complete Resolution of Nonalcoholic Fatty Liver Disease After Bariatric Surgery: A Systematic Review and Meta-analysis","volume":"17","author":"Lee","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1381\/096089206776116462","article-title":"Roux-en-Y gastric bypass improves the nonalcoholic steatohepatitis (NASH) of morbid obesity","volume":"16","author":"Rocha","year":"2006","journal-title":"Obes. Surg."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1053\/j.gastro.2015.04.014","article-title":"Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients","volume":"149","author":"Lassailly","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Chavez-Tapia, N.C., Tellez-Avila, F.I., Barrientos-Gutierrez, T., Mendez-Sanchez, N., Lizardi-Cervera, J., and Uribe, M. (2010). Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Syst. Rev., CD007340.","DOI":"10.1002\/14651858.CD007340.pub2"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.clnu.2014.03.010","article-title":"Physical exercise antagonizes clinical and anatomical features characterizing Lieber-DeCarli diet-induced obesity and related metabolic disorders","volume":"34","author":"Goncalves","year":"2015","journal-title":"Clin. Nutr."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1080\/00365520802555991","article-title":"Alcohol consumption is associated with progression of hepatic fibrosis in non-alcoholic fatty liver disease","volume":"44","author":"Ekstedt","year":"2009","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1111\/jgh.15027","article-title":"Endogenous ethanol produced by intestinal bacteria induces mitochondrial dysfunction in non-alcoholic fatty liver disease","volume":"35","author":"Chen","year":"2020","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1002\/hep.22848","article-title":"Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease","volume":"49","author":"Miele","year":"2009","journal-title":"Hepatology"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/gutjnl-2016-312431","article-title":"Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease","volume":"66","author":"Rotman","year":"2017","journal-title":"Gut"},{"key":"ref_172","first-page":"CD011640","article-title":"Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): An attempted network meta-analysis","volume":"3","author":"Lombardi","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/liv.12570","article-title":"The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis","volume":"35","author":"Barreyro","year":"2015","journal-title":"Liver Int."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1586\/egh.11.6","article-title":"Apoptosis in nonalcoholic fatty liver disease: Diagnostic and therapeutic implications","volume":"5","author":"Alkhouri","year":"2011","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1111\/j.1365-2036.2010.04467.x","article-title":"Meta-analysis: Insulin sensitizers for the treatment of non-alcoholic steatohepatitis","volume":"32","author":"Rakoski","year":"2010","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3892\/br.2012.18","article-title":"Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis","volume":"1","author":"Li","year":"2013","journal-title":"Biomed. Rep."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2008.06.047","article-title":"Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis","volume":"135","author":"Aithal","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S1542-3565(04)00457-4","article-title":"A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis","volume":"2","author":"Sanyal","year":"2004","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1002\/hep.25887","article-title":"Pioglitazone and vitamin E for nonalcoholic steatohepatitis: A cost utility analysis","volume":"56","author":"Mahady","year":"2012","journal-title":"Hepatology"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/jamainternmed.2016.9607","article-title":"Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis","volume":"177","author":"Musso","year":"2017","journal-title":"JAMA Intern. Med."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1002\/hep.27999","article-title":"Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis","volume":"62","author":"Singh","year":"2015","journal-title":"Hepatology"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1002\/hep.1840380427","article-title":"Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone","volume":"38","author":"Brunt","year":"2003","journal-title":"Hepatology"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/hep.23270","article-title":"Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial","volume":"51","author":"Ratziu","year":"2010","journal-title":"Hepatology"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1053\/j.gastro.2008.03.078","article-title":"Rosiglitazone for nonalcoholic steatohepatitis: One-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial","volume":"135","author":"Ratziu","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1177\/1756283X15611581","article-title":"Practice patterns in NAFLD and NASH: Real life differs from published guidelines","volume":"9","author":"Rinella","year":"2016","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.jhep.2019.10.023","article-title":"Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study","volume":"72","author":"Harrison","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/hep.26461","article-title":"Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha\/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"58","author":"Staels","year":"2013","journal-title":"Hepatology"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1177\/1479164114548027","article-title":"The dual peroxisome proliferator-activated receptor alpha\/delta agonist GFT505 exerts anti-diabetic effects in db\/db mice without peroxisome proliferator-activated receptor gamma\u2013associated adverse cardiac effects","volume":"11","author":"Hanf","year":"2014","journal-title":"Diabetes Vasc. Dis. Res."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.2337\/dc12-2012","article-title":"Dual peroxisome proliferator-activated receptor alpha\/delta agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects","volume":"36","author":"Cariou","year":"2013","journal-title":"Diabetes Care"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-alpha and -delta, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_194","first-page":"1484A","article-title":"A phase 2, prospective, multicenter, double-blind, randomized study of saroglitazar magnesium 1 mg, 2 mg or 4 mg versus placebo in patients with nonalcoholic fatty liver disease and\/or nonalcoholic steatohepatitis (EVIDENCES IV)","volume":"70","author":"Gawrieh","year":"2019","journal-title":"Hepatology"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"706416","DOI":"10.1155\/2015\/706416","article-title":"Liraglutide, a glucagon-like peptide-1 analog, increased insulin sensitivity assessed by hyperinsulinemic-euglycemic clamp examination in patients with uncontrolled type 2 diabetes mellitus","volume":"2015","author":"Jinnouchi","year":"2015","journal-title":"J. Diabetes Res."},{"key":"ref_196","first-page":"407","article-title":"Effect of Liraglutide Therapy on Liver Fat Content in Patients With Inadequately Controlled Type 2 Diabetes: The Lira-NAFLD Study","volume":"102","author":"Petit","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/apt.12149","article-title":"Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: Individual patient data meta-analysis of the LEAD program","volume":"37","author":"Armstrong","year":"2013","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"ref_199","first-page":"1354A","article-title":"Holistic effects of cotadutide (medi0382) on metabolic, cardiovascular, and hepatic parameters in overweight or obese subjects with type 2 diabetes mellitus (T2DM): A 26-week analysis of a randomized phase 2b study","volume":"70","author":"Nahra","year":"2019","journal-title":"Hepatology"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1053\/j.gastro.2018.07.027","article-title":"GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease","volume":"155","author":"Loomba","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.cmet.2017.08.011","article-title":"Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation","volume":"26","author":"Kim","year":"2017","journal-title":"Cell Metab."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.jcmgh.2020.07.002","article-title":"Acetyl-CoA Carboxylase Inhibition as a Therapeutic Tool in the Battle Against NASH: Hitting More Than Just One Mechanism?","volume":"10","author":"Lambrecht","year":"2020","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"ref_203","first-page":"21A","article-title":"PF-05221304 (PF\u20191304), A liver-targeted Acetyl-CoA Carboxylase Inhibitor (ACCI), in adults with nonalcoholic fatty liver disease (NAFLD) demonstrates robust reductions in liver fat and ALT-phase 2a, dose-ranging study","volume":"70","author":"Amin","year":"2019","journal-title":"Hepatology"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1136\/gutjnl-2019-319104","article-title":"Combination therapy for non-alcoholic steatohepatitis: Rationale, opportunities and challenges","volume":"69","author":"Dufour","year":"2020","journal-title":"Gut"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1016\/S0618-8278(19)30122-7","article-title":"PS-110-Ketohexokinase inhibitor PF-06835919 administered for 6 weeks reduces whole liver fat as measured by magnetic resonance imaging-proton density fat fraction in subjects with non-alcoholic fatty liver disease","volume":"70","author":"Calle","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/s41586-019-1095-5","article-title":"Structure of ATP citrate lyase and the origin of citrate synthase in the Krebs cycle","volume":"568","author":"Verschueren","year":"2019","journal-title":"Nature"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/s41575-019-0145-7","article-title":"From NASH to HCC: Current concepts and future challenges","volume":"16","author":"Anstee","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1053\/j.gastro.2013.05.042","article-title":"Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease","volume":"145","author":"Mudaliar","year":"2013","journal-title":"Gastroenterology"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"105803","DOI":"10.1016\/j.cct.2019.06.017","article-title":"REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis","volume":"84","author":"Ratziu","year":"2019","journal-title":"Contemp. Clin. Trials"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.cmet.2012.04.004","article-title":"Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease","volume":"15","author":"Min","year":"2012","journal-title":"Cell Metab."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: Interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"ref_212","doi-asserted-by":"crossref","unstructured":"Sanyal, A., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q., Goodman, Z., Bedossa, P., Khalili, M., Boursier, J., and Stinton, L. (2020, January 27). Obeticholic acid treatment in patients with non-alcoholic steatohepatitis: A secondary analysis in the regenerate study across fibrosis stages. Proceedings of the AISF Annual Meeting, Rome, Italy.","DOI":"10.1016\/j.dld.2019.12.043"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/j.dld.2019.12.129","article-title":"Tropifexor, a highly potent FXR agonist, produces robust and dose-dependent reductions in hepatic fat and serum alanine aminotransferase in patients with fibrotic NASH after 12 weeks of therapy: FLIGHT-FXR Part C interim results","volume":"52","author":"Lucas","year":"2020","journal-title":"Dig. Liver Dis."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1111\/liv.14490","article-title":"A novel non-bile acid FXR agonist EDP-305 potently suppresses liver injury and fibrosis without worsening of ductular reaction","volume":"40","author":"An","year":"2020","journal-title":"Liver Int."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/hep.30674","article-title":"MRI Assessment of Treatment Response in HIV-associated NAFLD: A Randomized Trial of a Stearoyl-Coenzyme-A-Desaturase-1 Inhibitor (ARRIVE Trial)","volume":"70","author":"Ajmera","year":"2019","journal-title":"Hepatology"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/hep4.1107","article-title":"Role of Aramchol in steatohepatitis and fibrosis in mice","volume":"1","author":"Delgado","year":"2017","journal-title":"Hepatol. Commun."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/j.cgh.2014.04.038","article-title":"The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease","volume":"12","author":"Safadi","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_218","first-page":"1448A","article-title":"One-year results of the global phase 2b randomized placebo-controlled arrest trial of aramchol, a stearoyl CoA desaturase inhibitor, in patients with NASH","volume":"68","author":"Ratziu","year":"2018","journal-title":"Hepatology"},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S2468-1253(19)30184-0","article-title":"Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: A double-blind, randomised, placebo-controlled, phase 2 dose-finding trial","volume":"4","author":"Traussnigg","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_220","first-page":"193","article-title":"Fibroblast Growth Factor Signaling in Metabolic Regulation","volume":"6","author":"Nies","year":"2015","journal-title":"Front. Endocrinol."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1210\/en.2003-1671","article-title":"Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes","volume":"145","author":"Fu","year":"2004","journal-title":"Endocrinology"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(18)30474-4","article-title":"NGM282 for treatment of non-alcoholic steatohepatitis: A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"391","author":"Harrison","year":"2018","journal-title":"Lancet"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1172\/JCI23606","article-title":"FGF-21 as a novel metabolic regulator","volume":"115","author":"Kharitonenkov","year":"2005","journal-title":"J. Clin. Investig."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1210\/er.2017-00016","article-title":"Fibroblast Growth Factor 21-Metabolic Role in Mice and Men","volume":"38","author":"Staiger","year":"2017","journal-title":"Endocr. Rev."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/S0140-6736(18)31785-9","article-title":"Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: A randomised, double-blind, placebo-controlled, phase 2a trial","volume":"392","author":"Sanyal","year":"2019","journal-title":"Lancet"},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3727\/105221616X691631","article-title":"Thyroid Hormone Receptor beta Agonist Induces beta-Catenin-Dependent Hepatocyte Proliferation in Mice: Implications in Hepatic Regeneration","volume":"17","author":"Alvarado","year":"2016","journal-title":"Gene Expr."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1080\/14656566.2018.1543403","article-title":"Present and emerging pharmacotherapies for non-alcoholic steatohepatitis in adults","volume":"20","author":"Ogawa","year":"2019","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1007\/s00125-018-4669-0","article-title":"The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure","volume":"61","author":"Thomas","year":"2018","journal-title":"Diabetologia"},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00125-018-4675-2","article-title":"Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: A double-blind randomised placebo-controlled study","volume":"61","author":"Eriksson","year":"2018","journal-title":"Diabetologia"},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2337\/dc18-1569","article-title":"The SGLT2 inhibitor dapagliflozin reduces liver fat but does not affect tissue insulin sensitivity: A randomized, double-blind, placebo-controlled study with 8-week treatment in type 2 diabetes patients","volume":"42","author":"Honka","year":"2019","journal-title":"Diabetes Care"},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1007\/s00125-018-4702-3","article-title":"Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: Results from randomised trials including the EMPA-REG OUTCOME\u00ae trial","volume":"61","author":"Sattar","year":"2018","journal-title":"Diabetologia"},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s00535-017-1364-8","article-title":"Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: Pooled and subgroup analyses of clinical trials","volume":"53","author":"Seko","year":"2018","journal-title":"J. Gastroenterol."},{"key":"ref_233","first-page":"1482A","article-title":"LIK066 (Licogliflozin), AN SGLT1\/2 inhibitor, robustly decreases alt and improves markers of hepatic and metabolic health in patients with non-alcoholic fatty liver disease: Interim analysis of a 12-week, randomized, placebo-controlled, phase 2a study","volume":"70","author":"Harrison","year":"2019","journal-title":"Hepatology"},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1002\/hep.30537","article-title":"F-box\/WD Repeat-Containing Protein 5 Mediates the Ubiquitination of Apoptosis Signal-Regulating Kinase 1 and Exacerbates Nonalcoholic Steatohepatitis in Mice","volume":"70","author":"Bai","year":"2019","journal-title":"Hepatology"},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/hep.29514","article-title":"The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial","volume":"67","author":"Loomba","year":"2018","journal-title":"Hepatology"},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nm.4453","article-title":"The deubiquitinating enzyme TNFAIP3 mediates inactivation of hepatic ASK1 and ameliorates nonalcoholic steatohepatitis","volume":"24","author":"Zhang","year":"2018","journal-title":"Nat. Med."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/nm.4290","article-title":"Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates","volume":"23","author":"Wang","year":"2017","journal-title":"Nat. Med."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/hep.29477","article-title":"A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis","volume":"67","author":"Friedman","year":"2018","journal-title":"Hepatology"},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0168-8278(18)30221-6","article-title":"Cenicriviroc treatment for adults with non-alcoholic steatohepatitis: Year 2 analysis of the phase 2B CENTAUR study","volume":"68","author":"Ratziu","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"10592","DOI":"10.1038\/ncomms10592","article-title":"Hepatocyte TRAF3 promotes liver steatosis and systemic insulin resistance through targeting TAK1-dependent signalling","volume":"7","author":"Wang","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nm.4461","article-title":"The deubiquitinating enzyme cylindromatosis mitigates nonalcoholic steatohepatitis","volume":"24","author":"Ji","year":"2018","journal-title":"Nat. Med."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1053\/j.gastro.2019.11.296","article-title":"Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension","volume":"158","author":"Chalasani","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"42801","DOI":"10.1038\/srep42801","article-title":"BAR502, a dual FXR and GPBAR1 agonist, promotes browning of white adipose tissue and reverses liver steatosis and fibrosis","volume":"7","author":"Carino","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.cld.2017.08.009","article-title":"The Intestinal Microbiome in Nonalcoholic Fatty Liver Disease","volume":"22","author":"Puri","year":"2018","journal-title":"Clin. Liver Dis."},{"key":"ref_246","first-page":"39","article-title":"Therapeutic Options in Non-Alcoholic Steatohepatitis (NASH). Are all Agents Alike? Results of a Preliminary Study","volume":"16","author":"Georgescu","year":"2007","journal-title":"J. Gastrointestin. Liver Dis."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.metabol.2008.07.030","article-title":"Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia","volume":"57","author":"Hyogo","year":"2008","journal-title":"Metab. Clin. Exp."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jhep.2015.05.006","article-title":"Statin use and non-alcoholic steatohepatitis in at risk individuals","volume":"63","author":"Dongiovanni","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"6170","DOI":"10.1039\/C9FO01373C","article-title":"High-fat diet induces mouse liver steatosis with a concomitant decline in energy metabolism: Attenuation by eicosapentaenoic acid (EPA) or hydroxytyrosol (HT) supplementation and the additive effects upon EPA and HT co-administration","volume":"10","author":"Echeverria","year":"2019","journal-title":"Food Funct."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.jhep.2011.08.018","article-title":"Omega-3 supplementation and non-alcoholic fatty liver disease: A systematic review and meta-analysis","volume":"56","author":"Parker","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"792","DOI":"10.3109\/09637486.2010.487480","article-title":"Effects of a 1-year dietary intervention with n-3 polyunsaturated fatty acid-enriched olive oil on non-alcoholic fatty liver disease patients: A preliminary study","volume":"61","author":"Sofi","year":"2010","journal-title":"Int. J. Food Sci. Nutr."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1002\/hep.21763","article-title":"A lipidomic analysis of nonalcoholic fatty liver disease","volume":"46","author":"Puri","year":"2007","journal-title":"Hepatology"},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1053\/j.gastro.2014.04.046","article-title":"No Significant Effects of Ethyl-Eicosapentanoic Acid on Histologic Features of Nonalcoholic Steatohepatitis in a Phase 2 Trial","volume":"147","author":"Sanyal","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1016\/j.cgh.2019.04.061","article-title":"Daily Aspirin Use Associated With Reduced Risk For Fibrosis Progression In Patients With Nonalcoholic Fatty Liver Disease","volume":"17","author":"Simon","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.mito.2013.09.002","article-title":"Berberine reverts hepatic mitochondrial dysfunction in high-fat fed rats: A possible role for SirT3 activation","volume":"13","author":"Teodoro","year":"2013","journal-title":"Mitochondrion"},{"key":"ref_256","doi-asserted-by":"crossref","unstructured":"Yan, H.M., Xia, M.F., Wang, Y., Chang, X.X., Yao, X.Z., Rao, S.X., Zeng, M.S., Tu, Y.F., Feng, R., and Jia, W.P. (2015). Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0134172"},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.2353\/ajpath.2009.080697","article-title":"Oxidative stress-mediated mitochondrial dysfunction contributes to angiotensin II-induced nonalcoholic fatty liver disease in transgenic Ren2 rats","volume":"174","author":"Wei","year":"2009","journal-title":"Am. J. Pathol."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.freeradbiomed.2020.02.029","article-title":"Mitochondrial superoxide\/hydrogen peroxide: An emerging therapeutic target for metabolic diseases","volume":"152","author":"Yan","year":"2020","journal-title":"Free Radic. Biol. Med."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1055\/s-2001-12929","article-title":"Mitochondria in steatohepatitis","volume":"21","author":"Pessayre","year":"2001","journal-title":"Semin. Liver Dis."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jhep.2011.06.010","article-title":"Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review","volume":"56","author":"Thoma","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"e1900043","DOI":"10.1002\/mnfr.201900043","article-title":"Mitochondria-Mediated Pathogenesis and Therapeutics for Non-Alcoholic Fatty Liver Disease","volume":"63","author":"Li","year":"2019","journal-title":"Mol. Nutr. Food Res."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/hepr.12634","article-title":"Liraglutide ameliorates non-alcoholic fatty liver disease by enhancing mitochondrial architecture and promoting autophagy through the SIRT1\/SIRT3-FOXO3a pathway","volume":"46","author":"Tong","year":"2016","journal-title":"Hepatol. Res. Off. J. Jpn. Soc. Hepatol."},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.cell.2009.03.016","article-title":"Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein","volume":"137","author":"He","year":"2009","journal-title":"Cell"},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3389\/fphar.2017.00545","article-title":"Pioglitazone Improves Mitochondrial Function in the Remnant Kidney and Protects against Renal Fibrosis in 5\/6 Nephrectomized Rats","volume":"8","author":"Sun","year":"2017","journal-title":"Front. Pharmacol."},{"key":"ref_265","doi-asserted-by":"crossref","unstructured":"Chen, Y.S., Liu, H.M., and Lee, T.Y. (2019). Ursodeoxycholic Acid Regulates Hepatic Energy Homeostasis and White Adipose Tissue Macrophages Polarization in Leptin-Deficiency Obese Mice. Cells, 8.","DOI":"10.3390\/cells8030253"},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"613","DOI":"10.2337\/db16-0663","article-title":"An Intestinal Farnesoid X Receptor-Ceramide Signaling Axis Modulates Hepatic Gluconeogenesis in Mice","volume":"66","author":"Xie","year":"2017","journal-title":"Diabetes"},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.3748\/wjg.v23.i23.4146","article-title":"Antioxidant dietary approach in treatment of fatty liver: New insights and updates","volume":"23","author":"Ferramosca","year":"2017","journal-title":"World J. Gastroenterol. WJG"},{"key":"ref_268","doi-asserted-by":"crossref","unstructured":"Ding, S., Jiang, J., Zhang, G., Bu, Y., Zhang, G., and Zhao, X. (2017). Resveratrol and caloric restriction prevent hepatic steatosis by regulating SIRT1-autophagy pathway and alleviating endoplasmic reticulum stress in high-fat diet-fed rats. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0183541"},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11010-016-2807-x","article-title":"Resveratrol supplement inhibited the NF-\u03baB inflammation pathway through activating AMPK\u03b1-SIRT1 pathway in mice with fatty liver","volume":"422","author":"Tian","year":"2016","journal-title":"Mol. Cell. Biochem."},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/j.1745-7254.2008.00807.x","article-title":"Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase","volume":"29","author":"Shang","year":"2008","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.febslet.2004.06.045","article-title":"Fine-tuning the hydrophobicity of a mitochondria-targeted antioxidant","volume":"571","author":"Manas","year":"2004","journal-title":"FEBS Lett."},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00232-008-9124-6","article-title":"Kinetic analysis of permeation of mitochondria-targeted antioxidants across bilayer lipid membranes","volume":"224","author":"Rokitskaya","year":"2008","journal-title":"J. Membr. Biol."},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"5407","DOI":"10.1073\/pnas.0931245100","article-title":"Delivery of bioactive molecules to mitochondria in vivo","volume":"100","author":"Smith","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.3748\/wjg.v19.i20.3007","article-title":"A silybin-phospholipids complex counteracts rat fatty liver degeneration and mitochondrial oxidative changes","volume":"19","author":"Grattagliano","year":"2013","journal-title":"World J. Gastroenterol. WJG"},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"6016","DOI":"10.3748\/wjg.v22.i26.6016","article-title":"Silybin counteracts lipid excess and oxidative stress in cultured steatotic hepatic cells","volume":"22","author":"Vecchione","year":"2016","journal-title":"World J. Gastroenterol. WJG"},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"4737","DOI":"10.1021\/jf904593n","article-title":"Antioxidant activities and xanthine oxidase inhibitory effects of extracts and main polyphenolic compounds obtained from Geranium sibiricum L.","volume":"58","author":"Wu","year":"2010","journal-title":"J. Agric. Food Chem."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1096\/fasebj.30.1_supplement.915.29","article-title":"Anthocyanins Improved Mitochondrial Dysfunction in Mice of Non-alcoholic Fatty Liver Disease Induced by High Fat Diet","volume":"30","author":"Ling","year":"2016","journal-title":"FASEB J."},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1021\/jf504926n","article-title":"Purified anthocyanins from bilberry and black currant attenuate hepatic mitochondrial dysfunction and steatohepatitis in mice with methionine and choline deficiency","volume":"63","author":"Tang","year":"2015","journal-title":"J. Agric. Food Chem."},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1089\/ars.2017.7172","article-title":"Dihydromyricetin ameliorates nonalcoholic fatty liver disease by improving mitochondrial respiratory capacity and redox homeostasis through modulation of SIRT3 signaling","volume":"30","author":"Zeng","year":"2019","journal-title":"Antioxid. Redox Signal."},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1053\/j.gastro.2016.08.027","article-title":"In children with nonalcoholic fatty liver disease, cysteamine bitartrate delayed release improves liver enzymes but does not reduce disease activity scores","volume":"151","author":"Schwimmer","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1111\/j.1365-2036.2011.04626.x","article-title":"Enteric-coated cysteamine for the treatment of paediatric non-alcoholic fatty liver disease","volume":"33","author":"Dohil","year":"2011","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"33102","DOI":"10.1038\/srep33102","article-title":"Pentoxifylline ameliorates non-alcoholic fatty liver disease in hyperglycaemic and dyslipidaemic mice by upregulating fatty acid beta-oxidation","volume":"6","author":"Ye","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"S-936","DOI":"10.1016\/S0016-5085(12)63630-0","article-title":"932 Pentoxifylline Improves Non-Invasive Serum Markers of Fibrosis: Combined Results From 2 Randomized, Placebo-Controlled Trials","volume":"142","author":"Zein","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1002\/hep.24544","article-title":"Pentoxifylline improves nonalcoholic steatohepatitis: A randomized placebo-controlled trial","volume":"54","author":"Zein","year":"2011","journal-title":"Hepatology"},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s10863-015-9630-z","article-title":"Letter to the Editor: The bioenergetics of hepatic mitochondria isolated from avocado oil-treated rats: Typical experimental errors in the study of the bioenergetics of isolated mitochondria","volume":"47","author":"Rendon","year":"2015","journal-title":"J. Bioenerg. Biomembr."},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s10863-015-9614-z","article-title":"Protective effects of dietary avocado oil on impaired electron transport chain function and exacerbated oxidative stress in liver mitochondria from diabetic rats","volume":"47","year":"2015","journal-title":"J. Bioenerg. Biomembr."},{"key":"ref_287","first-page":"660","article-title":"Avocado Oil Ameliorates Non-Alcoholic Fatty Liver Disease by Down-Regulating Inflammatory Cytokines and Improving Mitochondrial Dynamics","volume":"33","author":"Orozco","year":"2019","journal-title":"FASEB J."},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3389\/fphar.2017.00241","article-title":"Mitotherapy for Fatty Liver by Intravenous Administration of Exogenous Mitochondria in Male Mice","volume":"8","author":"Fu","year":"2017","journal-title":"Front. Pharmacol."},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/1440-1681.12886","article-title":"Role of mitochondria and mitochondria-targeted agents in non-alcoholic fatty liver disease","volume":"45","author":"Ajith","year":"2018","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.jhep.2005.03.004","article-title":"NASH: A mitochondrial disease","volume":"42","author":"Pessayre","year":"2005","journal-title":"J. Hepatol."},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"E5896","DOI":"10.1073\/pnas.1801745115","article-title":"Chemoproteomics reveals baicalin activates hepatic CPT1 to ameliorate diet-induced obesity and hepatic steatosis","volume":"115","author":"Dai","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.freeradbiomed.2017.10.232","article-title":"Nitro-oleic Acid Protects Mice from Diet-Induced Hepatic Steatosis and Insulin Resistance without the Adverse Side Effects of Thiazolidinediones","volume":"112","author":"Fazzari","year":"2017","journal-title":"Free Radic. Biol. Med."},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms14477","article-title":"Mitochondrial ATP transporter depletion protects mice against liver steatosis and insulin resistance","volume":"8","author":"Cho","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_294","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.clnu.2017.05.028","article-title":"Genistein supplementation improves insulin resistance and inflammatory state in non-alcoholic fatty liver patients: A randomized, controlled trial","volume":"37","author":"Amanat","year":"2018","journal-title":"Clin. Nutr."},{"key":"ref_295","first-page":"1489A","article-title":"Fenofibrate mitigates increases in serum triglycerides due to the ACC inhibitor firsocostat in patients with advanced fibrosis due to NASH: A phase 2 randomized trial","volume":"70","author":"Lawitz","year":"2019","journal-title":"Hepatology"},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.molmet.2019.11.015","article-title":"Physical exercise and liver \u201cfitness\u201d: Role of mitochondrial function and epigenetics-related mechanisms in non-alcoholic fatty liver disease","volume":"32","author":"Stevanovic","year":"2020","journal-title":"Mol. Metab."},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1139\/h11-076","article-title":"Skeletal muscle and beyond: The role of exercise as a mediator of systemic mitochondrial biogenesis","volume":"36","author":"Little","year":"2011","journal-title":"Appl. Physiol. Nutr. Metab. Physiol. Appl. Nutr. Metab."},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1006\/abbi.1996.0283","article-title":"Antioxidants, tissue damage, and endurance in trained and untrained young male rats","volume":"331","author":"Venditti","year":"1996","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.mito.2013.07.002","article-title":"Modulation of hepatic redox status and mitochondrial metabolism by exercise: Therapeutic strategy for liver diseases","volume":"13","author":"Ascensao","year":"2013","journal-title":"Mitochondrion"},{"key":"ref_300","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.1113\/jphysiol.2008.156745","article-title":"Cessation of daily exercise dramatically alters precursors of hepatic steatosis in Otsuka Long-Evans Tokushima Fatty (OLETF) rats","volume":"586","author":"Rector","year":"2008","journal-title":"J. Physiol."},{"key":"ref_301","doi-asserted-by":"crossref","first-page":"G619","DOI":"10.1152\/ajpgi.00428.2007","article-title":"Daily exercise increases hepatic fatty acid oxidation and prevents steatosis in Otsuka Long-Evans Tokushima Fatty rats","volume":"294","author":"Rector","year":"2008","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_302","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.lfs.2009.11.003","article-title":"Endurance exercise causes mitochondrial and oxidative stress in rat liver: Effects of a combination of mitochondrial targeting nutrients","volume":"86","author":"Sun","year":"2010","journal-title":"Life Sci."},{"key":"ref_303","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.cell.2012.02.017","article-title":"Mechanisms for insulin resistance: Common threads and missing links","volume":"148","author":"Samuel","year":"2012","journal-title":"Cell"},{"key":"ref_304","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1126\/science.1204265","article-title":"Human fatty liver disease: Old questions and new insights","volume":"332","author":"Cohen","year":"2011","journal-title":"Science"},{"key":"ref_305","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12966-015-0292-3","article-title":"Systematic literature review of determinants of sedentary behaviour in older adults: A DEDIPAC study","volume":"12","author":"Chastin","year":"2015","journal-title":"Int. J. Behav. Nutr. Phys. Act."},{"key":"ref_306","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nrendo.2016.135","article-title":"PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD","volume":"13","author":"Gross","year":"2017","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_307","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jhep.2014.10.039","article-title":"Molecular mechanism of PPARalpha action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease","volume":"62","author":"Pawlak","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_308","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/hep.23623","article-title":"A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease","volume":"52","author":"Musso","year":"2010","journal-title":"Hepatology"},{"key":"ref_309","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/MOL.0b013e32835cc949","article-title":"Peroxisome proliferator-activated receptor delta: A multifaceted metabolic player","volume":"24","author":"Bojic","year":"2013","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_310","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.cmet.2008.04.003","article-title":"Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance","volume":"7","author":"Odegaard","year":"2008","journal-title":"Cell Metab."},{"key":"ref_311","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2337\/db07-1318","article-title":"Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men","volume":"57","author":"Riserus","year":"2008","journal-title":"Diabetes"},{"key":"ref_312","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/hep.20012","article-title":"A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis","volume":"39","author":"Promrat","year":"2004","journal-title":"Hepatology"},{"key":"ref_313","doi-asserted-by":"crossref","unstructured":"Colca, J.R., McDonald, W.G., Cavey, G.S., Cole, S.L., Holewa, D.D., Brightwell-Conrad, A.S., Wolfe, C.L., Wheeler, J.S., Coulter, K.R., and Kilkuskie, P.M. (2013). Identification of a mitochondrial target of thiazolidinedione insulin sensitizers (mTOT)--relationship to newly identified mitochondrial pyruvate carrier proteins. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0061551"},{"key":"ref_314","doi-asserted-by":"crossref","first-page":"E163","DOI":"10.1152\/ajpendo.00023.2018","article-title":"Pioglitazone improves hepatic mitochondrial function in a mouse model of nonalcoholic steatohepatitis","volume":"315","author":"Kalavalapalli","year":"2018","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_315","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.cmet.2015.07.028","article-title":"Loss of Mitochondrial Pyruvate Carrier 2 in the Liver Leads to Defects in Gluconeogenesis and Compensation via Pyruvate-Alanine Cycling","volume":"22","author":"McCommis","year":"2015","journal-title":"Cell Metab."},{"key":"ref_316","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/febs.13992","article-title":"Pioglitazone inhibits mitochondrial pyruvate metabolism and glucose production in hepatocytes","volume":"284","author":"Shannon","year":"2017","journal-title":"FEBS J."},{"key":"ref_317","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jhep.2016.04.021","article-title":"Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial","volume":"65","author":"Cui","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_318","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3748\/wjg.v23.i1.141","article-title":"Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial","volume":"23","author":"Joy","year":"2017","journal-title":"World J. Gastroenterol. WJG"},{"key":"ref_319","first-page":"64","article-title":"Effect of metformin on mitochondrial pathway of apoptosis and oxidative stress in cell model of nonalcoholic fatty liver disease","volume":"28","author":"Wu","year":"2020","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"ref_320","doi-asserted-by":"crossref","first-page":"172715","DOI":"10.1016\/j.ejphar.2019.172715","article-title":"Liraglutide ameliorates non-alcoholic steatohepatitis by inhibiting NLRP3 inflammasome and pyroptosis activation via mitophagy","volume":"864","author":"Yu","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"ref_321","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1172\/JCI21025","article-title":"Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c","volume":"113","author":"Watanabe","year":"2004","journal-title":"J. Clin. Investig."},{"key":"ref_322","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1194\/jlr.R024794","article-title":"Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease Thematic Review Series: New Lipid and Lipoprotein Targets for the Treatment of Cardiometabolic Diseases","volume":"53","author":"Porez","year":"2012","journal-title":"J. Lipid Res."},{"key":"ref_323","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nrm3312","article-title":"Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR","volume":"13","author":"Calkin","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_324","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.cmet.2013.03.013","article-title":"Pleiotropic roles of bile acids in metabolism","volume":"17","author":"Tarling","year":"2013","journal-title":"Cell Metab."},{"key":"ref_325","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.cytogfr.2015.07.016","article-title":"Mechanisms of enterohepatic fibroblast growth factor 15\/19 signaling in health and disease","volume":"26","author":"Jahn","year":"2015","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_326","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0168-8278(01)00092-7","article-title":"Ursodeoxycholic acid \u2018mechanisms of action and clinical use in hepatobiliary disorders\u2019","volume":"35","author":"Lazaridis","year":"2001","journal-title":"J. Hepatol."},{"key":"ref_327","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/hep.510230624","article-title":"Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: A pilot study","volume":"23","author":"Laurin","year":"1996","journal-title":"Hepatology"},{"key":"ref_328","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.jhep.2014.12.034","article-title":"Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity","volume":"62","author":"Mueller","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_329","first-page":"471","article-title":"Toxicity of bile acids on the electron transport chain of isolated rat liver mitochondria","volume":"19","author":"Krahenbuhl","year":"1994","journal-title":"Hepatology"},{"key":"ref_330","first-page":"607","article-title":"Reduced antioxidative capacity in liver mitochondria from bile duct ligated rats","volume":"22","author":"Krahenbuhl","year":"1995","journal-title":"Hepatology"},{"key":"ref_331","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/toxsci\/57.1.177","article-title":"Bile acids affect liver mitochondrial bioenergetics: Possible relevance for cholestasis therapy","volume":"57","author":"Rolo","year":"2000","journal-title":"Toxicol. Sci. An. Off. J. Soc. Toxicol."},{"key":"ref_332","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1002\/hep.1840200632","article-title":"Ursodeoxycholate protects oxidative mitochondrial metabolism from bile acid toxicity: Dose-response study in isolated rat liver mitochondria","volume":"20","author":"Krahenbuhl","year":"1994","journal-title":"Hepatology"},{"key":"ref_333","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat. Med."},{"key":"ref_334","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/112_2018_10","article-title":"Targeting Oxidative Stress for the Treatment of Liver Fibrosis","volume":"175","author":"Luangmonkong","year":"2018","journal-title":"Rev. Physiol. Biochem. Pharmacol."},{"key":"ref_335","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1172\/JCI76738","article-title":"Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease","volume":"125","author":"Jiang","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_336","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1016\/j.cgh.2014.02.024","article-title":"Resveratrol does not benefit patients with nonalcoholic fatty liver disease","volume":"12","author":"Chachay","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_337","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.3109\/10715762.2014.945079","article-title":"The mitochondrial-targeted antioxidant MitoQ ameliorates metabolic syndrome features in obesogenic diet-fed rats better than Apocynin or Allopurinol","volume":"48","author":"Fouret","year":"2014","journal-title":"Free Radic. Res."},{"key":"ref_338","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.bbabio.2015.05.019","article-title":"The mitochondrial-targeted antioxidant, MitoQ, increases liver mitochondrial cardiolipin content in obesogenic diet-fed rats","volume":"1847","author":"Fouret","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_339","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.freeradbiomed.2011.11.026","article-title":"The mitochondria-targeted antioxidant MitoQ decreases features of the metabolic syndrome in ATM+\/-\/ApoE-\/- mice","volume":"52","author":"Mercer","year":"2012","journal-title":"Free Radic. Biol. Med."},{"key":"ref_340","doi-asserted-by":"crossref","first-page":"37575","DOI":"10.1074\/jbc.M404003200","article-title":"Supplementation of endothelial cells with mitochondria-targeted antioxidants inhibit peroxide-induced mitochondrial iron uptake, oxidative damage, and apoptosis","volume":"279","author":"Dhanasekaran","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_341","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1478-3231.2010.02250.x","article-title":"The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients","volume":"30","author":"Gane","year":"2010","journal-title":"Liver Int."},{"key":"ref_342","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.tifs.2016.11.019","article-title":"Beneficial effects of the Mediterranean spices and aromas on non-alcoholic fatty liver disease","volume":"61","author":"Rachid","year":"2017","journal-title":"Trends Food Sci. Technol."},{"key":"ref_343","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.2165\/00003495-200161140-00003","article-title":"The use of silymarin in the treatment of liver diseases","volume":"61","author":"Saller","year":"2001","journal-title":"Drugs"},{"key":"ref_344","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.jhep.2009.02.023","article-title":"Silybin, a component of sylimarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells","volume":"50","author":"Trappoliere","year":"2009","journal-title":"J. Hepatol."},{"key":"ref_345","first-page":"9","article-title":"Silymarin in treatment of non-alcoholic steatohepatitis: A randomized clinical trial","volume":"5","author":"Solhi","year":"2014","journal-title":"Casp. J. Intern. Med."},{"key":"ref_346","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/j.freeradbiomed.2012.02.008","article-title":"Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: A randomized controlled trial","volume":"52","author":"Loguercio","year":"2012","journal-title":"Free Radic. Biol. Med."},{"key":"ref_347","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.yrtph.2007.03.006","article-title":"Dinitrophenol and obesity: An early twentieth-century regulatory dilemma","volume":"48","author":"Colman","year":"2007","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"ref_348","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.3389\/fphar.2019.01693","article-title":"Corilagin Alleviates Nonalcoholic Fatty Liver Disease in High-Fat Diet-Induced C57BL\/6 Mice by Ameliorating Oxidative Stress and Restoring Autophagic Flux","volume":"10","author":"Zhang","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_349","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1126\/science.aaa0672","article-title":"Controlled-release mitochondrial protonophore reverses diabetes and steatohepatitis in rats","volume":"347","author":"Perry","year":"2015","journal-title":"Science"},{"key":"ref_350","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2174\/1874467212666190920144115","article-title":"Mitotherapy as a Novel Therapeutic Strategy for Mitochondrial Diseases","volume":"13","author":"Fu","year":"2020","journal-title":"Curr. Mol. Pharmacol."},{"key":"ref_351","doi-asserted-by":"crossref","first-page":"6409","DOI":"10.1073\/pnas.0401627101","article-title":"Stearoyl-CoA desaturase 1 deficiency increases fatty acid oxidation by activating AMP-activated protein kinase in liver","volume":"101","author":"Dobrzyn","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_352","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1467-789X.2005.00177.x","article-title":"Stearoyl-CoA desaturase as a new drug target for obesity treatment","volume":"6","author":"Dobrzyn","year":"2005","journal-title":"Obes. Rev."},{"key":"ref_353","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.bcp.2009.10.005","article-title":"Genistein and daidzein prevent low potassium-dependent apoptosis of cerebellar granule cells","volume":"79","author":"Atlante","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"ref_354","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1111\/liv.14209","article-title":"CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients","volume":"39","author":"Pockros","year":"2019","journal-title":"Liver Int."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/10\/5375\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:04:35Z","timestamp":1760162675000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/10\/5375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,20]]},"references-count":354,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,5]]}},"alternative-id":["ijms22105375"],"URL":"https:\/\/doi.org\/10.3390\/ijms22105375","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,20]]}}}